Pumpinheart, a Royal College of Surgeons in Ireland (RCSI) spinout company, is developing a device to treat HFpEF.
The PReduction device (patent pending) is an ECG gated implantable diastolic pump in the left ventricle that reduces left atrial pressure during diastole and in sympathy with elevated pressures during exercise.
The sub-dermal power and control unit is connected to pressure sensors, an ECG sensor and the PReduction device in the left ventricle via a driveline in the left subclavian vein.
The PReduction device (patent pending) is powered and controlled by a Transcutaneous Energy Transfer System (TETS) and subdermal unit located below the left clavicle with the driveline wire delivered via catheter.
The PReduction Device (patent pending) is delivered via transcatheter implantation via femoral venous access in a cath lab by an interventional cardiologist.
The PReduction device aims to treat Stage C and D (NYHA classification) HFpEF ambulatory patients and enable HFpEF patients to survive HFpEF and live active lives at home.
The PReduction device is designed to be delivered in a cath lab with associated accessibility and short post operative recovery. The device promises to reduce HFpEF hospitalisations and the associated burden of cost on healthcare systems.
The PReduction device is at pre-clinical research phase and at least seven years years of further research and clinical trials are required before it shall be approved, certified and available.
Pumpinheart won Silver Award in National Startup Awards 2022 (Ireland) in the Medtech Startup category.
€3.14M awarded under DTIF Call 4 (2021 – 2022) to Pumpinheart-led consortium comprising Pumpinheart, Boston Scientific, Gentian Health and the Royal College of Surgeons in Ireland to support preclinical development of the PReduction Device to treat HFpEF.
The Wilson Sonsini (WSGR) MDC 2023 Medical Device Digital Health Conference event begins with a Reception and Dinner at the Sharon Heights Golf & Country Club, Menlo Park, California on Thursday, June 15, followed by the WSGR MDC conference on Friday, June 16, at the Palace Hotel, San Francisco.
The MedTech Innovator Accelerator 2023 Cohort program launches June 14-15, at the Innovator Summit at The Computer Museum, in Mountain View, California.
Pumpinheart advances to pitch at the MedTech Innovator event on 24th April in Dublin as part of the selection process in the MedTech Innovator 2023 Road Tour. The pitch event is co-located with MedTech Strategist conference 25th-27th April at The Shelbourne Hotel.
If you're interested in one of our open positions, start by applying here and attaching your resume.
Copyright © 2022 Pumpinheart Ltd - All Rights Reserved - Registered in Ireland at 12 Prince Edward Terrace, Blackrock, Co Dublin, A94W3V1 Company No. 712811 VAT No. IE 3956178GH Directors: J Bolger, J Bouchier Hayes, F H Cheema (USA), D N Colgan, P M Curtis, A Hameed, D A Hickey (Co. Sec.), A J Malone.